AbbVie: Colorectal Neoplasms trials

The registry lists 13 Colorectal Neoplasms studies with AbbVie as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 6Phase 2 6Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsRecruitingNCT07807956Phase 1
• A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerRecruitingNCT07525206Phase 3
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseRecruitingNCT07023289Phase 2
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingNCT06820463Phase 2
• A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and BevacizumabTerminatedNCT03368859Phase 2Results posted
• Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal CancerCompletedNCT02305758Phase 2Results posted
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerActive, not recruitingNCT06614192Phase 2
• Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerActive, not recruitingNCT06464692Phase 1
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingNCT05029882Phase 1
• A Study of SC-007 in Subjects With Advanced CancerTerminatedNCT03253185Phase 1
• A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal CancerTerminatedNCT03035279Phase 1
• A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorTerminatedNCT02365662Phase 1
• Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal CancerCompletedNCT00707889Phase 2